摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-butyl-N-methyl-2-naphthamide

中文名称
——
中文别名
——
英文名称
N-butyl-N-methyl-2-naphthamide
英文别名
N-butyl-N-methyl-naphthalene-2-carboxamide;N-butyl-N-methylnaphthalene-2-carboxamide
N-butyl-N-methyl-2-naphthamide化学式
CAS
——
化学式
C16H19NO
mdl
——
分子量
241.333
InChiKey
XNZZKQRYVHTRLW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    20.3
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

  • 作为产物:
    描述:
    参考文献:
    名称:
    Composition for treating depression with (N-heteroaryl)alkylamines
    摘要:
    该发明涉及具有以下结构式的化合物:##STR1##或其盐,其中E代表氢、较低的烷基或Ar.sup.1 --A.sup.1 --基团;Ar和Ar.sup.1是相同或不同的芳基团(包括杂环芳基),可以选择性地被一种或多种在药物化学中常用的取代基取代;A和A.sup.1是将Ar或Ar.sup.1与N连接的一个或两个碳原子的相同或不同的烷基基团,并且可以被较低的烷基和/或可选择性取代的芳基取代;B是一个由3或4个碳原子组成的烷基基团,可以被较低的烷基取代;D.sup.1代表卤素、CH.sub.3、CR.sup.1 R.sup.2 NH.sub.2、SO.sub.3 H或SO.sub.2 NR.sup.6 R.sup.7,其中R.sup.1和R.sup.2独立地代表氢或较低的烷基,R.sup.6和R.sup.7分别代表氢、较低的烷基或7至12个碳原子的芳基烷基,或者R.sup.6和R.sup.7与它们连接的氮原子一起代表一个5或6元环,这些化合物对于治疗动物的抑郁症、脑血供不足或痴呆症是有用的。
    公开号:
    US05422355A1
点击查看最新优质反应信息

文献信息

  • Sunlight assisted direct amide formation via a charge-transfer complex
    作者:Irit Cohen、Abhaya K. Mishra、Galit Parvari、Rachel Edrei、Mauricio Dantus、Yoav Eichen、Alex M. Szpilman
    DOI:10.1039/c7cc05300b
    日期:——
    We report on the use of charge-transfer complexes between amines and carbon tetrachloride, as novel way to activate the amine for photochemical reactions. This principle is demonstrated in a mild, transition metal free, visible light assisted, dealkylative amide formation from feedstock carboxylic acids and amines. The low absorption coefficient of the complex allows deep light penetration and thus
    我们报道了在胺和四氯化碳之间使用电荷转移络合物作为激活胺进行光化学反应的新方法。由原料羧酸和胺形成的温和,无过渡金属,可见光辅助的脱烷基酰胺证明了这一原理。络合物的低吸收系数允许深光穿透,因此可放大至克级。
  • Composition for treating depression with aralkyl amines
    申请人:John Wyeth & Brother Limited
    公开号:US05086073A1
    公开(公告)日:1992-02-04
    The invention concerns compounds having formula: ##STR1## or a salt thereof, wherein E represents hydrogen, lower alkyl or a group Ar.sup.1 --A.sup.1 ; Ar and Ar.sup.1 are the same or different aryl groups (including heteroaryl) which are optionally substituted, e.g. by one or more substituents commonly used in pharmaceutical chemistry; A and A.sup.1 are the same or different alkylene groups having one or two carbon atoms linking Ar or Ar.sup.1 to N and optionally substituted by lower alkyl and/or optionally substituted aryl, B is an alkylene group of 3 or 4 carbon atoms, which may be substituted by lower alkyl; D.sup.1 represents halogen, CH.sub.3, CR.sup.1 R.sup.2 NH.sub.2, SO.sub.3 H or SO.sub.2 NR.sup.6 R.sup.7 where R.sup.1 and R.sup.2 are independently hydrogen or lower alkyl and R.sup.6 and R.sup.7 are each hydrogen, lower alkyl or aralkyl of 7 to 12 carbon atoms or R.sup.6 and R.sup.7 together with the nitrogen atom to which they are attached represent a 5 or 6 membered ring, which compounds are useful, for treating depression or cerebral insufficiency or dementias in animals.
    这项发明涉及具有以下结构的化合物:##STR1##或其盐,其中E代表氢、较低的烷基或Ar.sup.1 --A.sup.1基团;Ar和Ar.sup.1是相同或不同的芳基团(包括杂环芳基),可以选择性地被一种或多种在药物化学中常用的取代基取代,A和A.sup.1是相同或不同的烷基烃基团,其中有一个或两个碳原子将Ar或Ar.sup.1连接到N,并且可以被较低的烷基和/或可选择地被取代的芳基取代,B是一个由3或4个碳原子组成的烷基基团,可以被较低的烷基取代;D.sup.1代表卤素、CH.sub.3、CR.sup.1 R.sup.2 NH.sub.2、SO.sub.3 H或SO.sub.2 NR.sup.6 R.sup.7,其中R.sup.1和R.sup.2独立地代表氢或较低的烷基,R.sup.6和R.sup.7分别代表氢、较低的烷基或7至12个碳原子的芳基烷基或R.sup.6和R.sup.7与它们连接的氮原子一起代表一个5或6元环,这些化合物可用于治疗动物的抑郁症、脑血供不足或痴呆症。
  • Composition for treating depression with (S- or O-heteroaryl)alkyl amines
    申请人:John Wyeth & Brother Limited
    公开号:US05260331A1
    公开(公告)日:1993-11-09
    The invention concerns compounds having formula: ##STR1## or a salt thereof, wherein E represents hydrogen, lower alkyl or a group Ar.sup.1 --A.sup.1 --; Ar and Ar.sup.1 are the same or different aryl groups (including heteroaryl) which are optionally substituted, e.g. by one or more substituents commonly used in pharmaceutical chemistry; A and A.sup.1 are the same or different alkylene groups having one or two carbon atoms linking Ar or Ar.sup.1 to N and optionally substituted by lower alkyl and/or optionally substituted aryl, B is an alkylene group of 3 or 4 carbon atoms, which may be substituted by lower alkyl; D.sup.1 represents halogen, CH.sub.3, CR.sup.1 R.sup.2 NH.sub.2, SO.sub.3 H or SO.sub.2 NR.sup.6 R.sup.7 where R.sup.1 and R.sup.2 are independently hydrogen or lower alkyl and R.sup.6 and R.sup.7 are each hydrogen, lower alkyl or aralkyl of 7 to 12 carbon atoms or R.sup.6 and R.sup.7 together with the nitrogen atom to which they are attached represent a 5 or 6 membered ring, which compounds are useful, for treating depression or cerebral insufficiency or dementias in animals.
    本发明涉及具有以下式的化合物:##STR1##或其盐,其中E代表氢、低烷基或Ar.sup.1--A.sup.1--基团;Ar和Ar.sup.1是相同或不同的芳基(包括杂芳基),可以选择地被一种或多种在制药化学中常用的取代基取代;A和A.sup.1是相同或不同的烷基链,具有将Ar或Ar.sup.1与N连接的一个或两个碳原子,并可以被低烷基和/或可选择地被取代的芳基取代;B是一个有3或4个碳原子的烷基链,可以被低烷基取代;D.sup.1代表卤素、CH.sub.3、CR.sup.1R.sup.2NH.sub.2、SO.sub.3H或SO.sub.2NR.sup.6R.sup.7,其中R.sup.1和R.sup.2分别是氢或低烷基,R.sup.6和R.sup.7分别是7到12个碳原子的氢、低烷基或芳基烷基,或者R.sup.6和R.sup.7与它们所连接的氮原子一起代表一个5或6元环。这些化合物用于治疗动物的抑郁症、脑血液不足或痴呆症。
  • Aromatic and heteroaromatic amines for treating depressions, cerebral insufficiency disorders or dementia
    申请人:JOHN WYETH & BROTHER LIMITED
    公开号:EP0407032B1
    公开(公告)日:1994-11-09
  • US5086073A
    申请人:——
    公开号:US5086073A
    公开(公告)日:1992-02-04
查看更多